

ARCUS OVERVIEW

NYSE: RCUS

ARCUS
BIOSCIENCES

Global, clinical-stage biopharmaceutical company at the forefront of designing novel combination therapies for cancer

HIGHLY PRODUCTIVE DRUG DISCOVERY

Small Molecules & Antibodies Designed to Be Combined



Targets: CD73, HIF-2α, A2α/2b, AXL



Targets: TIGIT, PD-1, CD39

Goal of 1-2
new molecules advancing
into clinic each year



Accelerated
P 1/2 signal-
seeking &
platform studies

DIVERSE PIPELINE & KEY DATA FOR 2025+

7



Different
molecules
in clinic

**1st Pivotal
Readout**



for Fc-silent anti-TIGIT
dom Phase 3 Study with
potential approval and
revenue generation
anticipated in 24-36
months

3+

**HIF-2α
Cas Events**



- Cas monotherapy
PFS data
- Cas + cabo efficacy data
- Additional data in
early-line settings

\$10B+



Addressable market
opportunity in the U.S.
based on expected
drug treatable patient
population

TOP-TIER PARTNERS FOR STRATEGIC & CLINICAL COLLABORATIONS



Funding:

~\$1.7B

- Holds ~30% equity stake in Arcus
- 50/50 Cost-sharing for certain optioned programs
- Co-development / co-commercialization in the U.S.



STRONG FINANCIAL POSITION & CASH RUNWAY WITH FUNDING THROUGH MULTIPLE PHASE 3 READOUTS



\$927M

cash, cash equivalents &
marketable securities as of 6/30/2025

HQ & RESEARCH CAMPUSES IN BAY AREA



~600

employees

Learn more at
investors.arcusbio.com

Except as stated otherwise, this summary is provided as of 8/6/2025. For a more complete description of our business and risks and uncertainties that may affect forward-looking statements made in this summary, including the statement regarding funding through multiple Phase 3 readouts, please refer to our full corporate presentation and latest Form 10-K and Form 10-Q, which can be found at investors.arcusbio.com. The runway estimate is based on cash, cash equivalents, marketable securities, and available facilities.

cabo: cabozantinib, cas: casdatifan, dom: domvanilimab, PFS: progression-free survival